Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'
February 27, 2024 12:06 PM ESTStifel analyst Samimy Annabel raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $80.00 (from $35.00) while maintaining a Buy rating.
The analyst comments "Ahead of schedule, VKTX released the Ph.2 VENTURE data for injectable-VK2735, which again demonstrated a highly competitive profile relative to... More
Viking Therapeutics (VKTX) stock surges after phase 2 Venture trial meets primary and secondary endpoints
February 27, 2024 8:40 AM ESTViking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its Phase 2 clinical trial of VK2735.
VK2735 is a medicine that may help treat obesity and other metabolic disorders. It works by targeting to... More
